<DOC>
	<DOCNO>NCT02589340</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy buspirone combination amantadine reduce levodopa-induced dyskinesia ( LID ) patient Parkinson 's disease ( PD ) .</brief_summary>
	<brief_title>Buspirone , Combination With Amantadine , Treatment Levodopa-induced Dyskinesia</brief_title>
	<detailed_description>Plan : We perform randomize , placebo-controlled , double-blind , two-period cross-over study evaluate safety , tolerability , efficacy novel treatment combination LID PD . Methods : Eligible subject consent participate study randomize one two sequence treatment intervention baseline visit . Each treatment sequence include placebo buspirone intervention . After randomization , participant titrate study drug two week end 30 mg/day . At end two week study drug period , participant study visit VA Portland Health Care System include safety monitoring , adverse event monitoring , drug compliance , several measurement LID .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Buspirone</mesh_term>
	<criteria>Parkinson 's disease diagnosis Currently take levodopa contain medication Parkinson 's disease Mild Severe dyskinesia Currently take 200500 mg amantadine daily treatment levodopainduced dyskinesia insufficient suppression levodopainduced dyskinesia . Stable medication regimen least 4 week prior study . Currently receive treatment levodopainduced dyskinesia , include exclusive deep brain stimulation . Not able follow verbal command Not able stand unsupported least 60 second Not able answer patient questionnaire symptom Parkinson 's disease dyskinesia . Have proprioceptive deficit . Have history hepatic impairment Currently severe renal impairment Currently medical psychiatric diagnosis would preclude ability safely participate study . Significant cognitive impairment Pregnancy BreastFeeding Unable swallow study drug ( capsule )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>